WSJ Article Comparing Sarepta (SRPT) and BioMarin (BMRN) 'Juvenile and Uninformed', Roth Capital Says

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. LEN
8. USO
9. LMT
10. AMZN

Go back to WSJ Article Comparing Sarepta (SRPT) and BioMarin (BMRN) 'Juvenile and Uninformed', Roth Capital Says

Sarepta Therapeutics Announces Plans to Submit Rolling NDA for Eteplirsen following Today’s Pre-NDA Meeting with the FDA

May 19, 2015 4:00 PM EDT

- Held pre-NDA meeting and agreed on rolling submission with the Agency -

- Will submit first two components of the NDA this week -

- Plans to complete the submission by mid-year -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the Company held a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding its lead product candidate, eteplirsen, for the... More